background external beam radiotherapy beta radioimmunotherapy rit effective treatments lymphoid malignancies development rit alpha emitters attractive high linear energy transfer let short path length allowing higher tumour cell kill lower toxicity healthy tissues aim assess binding rituximab samples b cell chronic lymphocytic leukaemia splenic lymphoma villous lymphocytes slvl evaluate induction apoptosis conventional therapies bi conjugated rituximab method 213bi eluted 225ac generator conjugated cd20 antibody rituximab chelator binding assays correlated antibody binding capacity obtained flow cytometry apoptosis scored flow cytometric analyses cells stained annexin d results binding significantly lower compared slvl samples 213bi atoms cell respectively NUMBER induction apoptosis did differ significantly groups slvl external gamma irradiation treatment methylprednisolone fludarabine respectively results expressed percentages cells rituximab conjugated 213bi induced significantly apoptosis slvl compared samples conclusion binding assays confirm slvl samples present cd20 antigens compared samples conventional therapies fludarabine methylprednisolone external gamma irradiation induce similar responses populations slvl samples present higher sensitivity data favour slvl patients b cll chx dtpa 213bi rituximab v fitc NUMBER amino actinomycin 213bi rituximab b cll NUMBER NUMBER kbqml NUMBER b cll NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER b cll NUMBER NUMBER b cll 213bi rituximab alpha rit NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER